{"ticker": {"uuid": "80fc85a8-250b-41ab-82fe-88061d88a387", "symbol": "CLYM", "name": "Climb Bio Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "FMR LLC's Strategic Acquisition of Climb Bio Inc Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPYU9PTHk0aUxpWUJKR1NrTGdwd255WTNXME5oa0xISTdfSVphTnB6bTZCSktPUmhLUXFIQWoySUMyUWlnLUZEa1FDS1MwaTN0bDY1eGZEWElXX1EtVHNBbklPbzdkVlQ5ZnhPVk0zMElQTVNmYnBKckV2V3dGdWVTN0xUV3pFYmVidi1Fc3JmR2FFX0h1cjF0SQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T00:59:19+00:00", "published_display": "15 Jul 2026 00:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Form 4 Climb Bio Inc For: 1 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOQ3J3bUZGT0dsZDhhQ2ZfTmw5WXFZbVBCOUgxZHVTVk8zTjhwZnpoZTBnSGlSc3dyNExSRkRMaGp6QTgzTHpMMmx1MWdPcDZ5U3dOVWVtd0FVMFgwcVpHTUdmbnhfcjRSN1NGT2ozY3dYR1JxbmE2T2ZkdW04QlBycVVyZ3NjMlVzS2VnNnd1aXc5ZEp3VmZv?oc=5", "source_name": "Investing.com UK", "published_at": "2026-07-01T21:57:23+00:00", "published_display": "01 Jul 2026 21:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio Insider Sold Shares Worth $406,979, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/climb-bio-insider-sold-shares-081533939.html", "source_name": "MT Newswires", "published_at": "2026-07-01T08:15:33+00:00", "published_display": "01 Jul 2026 08:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "70,284 Climb Bio (CLYM) share options granted for RA Capital-related funds", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQMVpMb2dHblV1OHNZR1VoU19BTjRKaXlMYm0teDhva3pmN1NqMmRIQ3RTVDhBcjFPdjd5M3JQVVBIZlVDRE5yajU3Skp3R1B4c09LaTA3TlVlOS1LZU82emc5RDVyYTFSRUltZTM5TUpwNm85YTRlX0VFdEkweFBHN1Q1b3I2LXRsWThaVmlOOS13Y0hUQWxHcW11VzVKRHVxcS1mM1RJdWRhUjg?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Climb Bio Inc For: 30 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPMk5YUUI4SkxIVjlENjdmUHY2TDF4TWtUWnlpeVdfRVk5ZzZudHBNb05QQjllLUxYQlZiT3hyQkpMd25wVVhMZl90VWNZS3ZRN0RqWXZqd2w5aWc4MVI2ZnNvWVN1MXBZMDE2dzhpSGtzNlozVGV6clVJTjJWQ3o4dWIyLVRJNG9IcUtNNW54T0ZXU2JYZ2x5RA?oc=5", "source_name": "Investing.com UK", "published_at": "2026-07-01T00:02:13+00:00", "published_display": "01 Jul 2026 00:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNX25QdlB1MG12TzVmNDRLWVZqdzRVZTRPNFltdEFYem5LUmRiODZ4aHlHLWZ4QnF1S0tkajg2X3E5dHUtU0MyYzNVUW1ITm40cUxvRTZIQ3lFWTRaTVNqSTlIRGFkRzZDdnJiSno4QnpuQWl2UlU3dFJ3NnlwX21kM3hDbzVWdHhVUmp6N0dHV0NzM2tBYWJRdy1rLWtFZHZ4bDQtQ0k2R292Mlg3?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-29T21:45:55+00:00", "published_display": "29 Jun 2026 21:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 3000E Growth Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQTmVxblFQUGJpQjBpZkRFMXVscWVVRzJKNjNIcTZlWEpNcy10d0xkZ2lFWkRReG9lLXpNYlRHMWx2em9Ya0pMYWMxd19Nc0lEaGVPOWtyQXlxOWtDM250ZldUeEYzcmtnWFl6SU5oNmQycHVGWmVsd3Z2MUVmNWxYNWFUOW0wM0c5blJrU2dvaWxqT3B0NFVnSGtMbVNtem9DaWt0bmhyTHVtN0FfMlhKUm1CVHNudVZDU09PWQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-29T08:46:02+00:00", "published_display": "29 Jun 2026 08:46", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 3000 Growth Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggJBVV95cUxNME1DMzBaZ0EzZ1N1enpxZGhpeG1PUW5FV3hOQktweEpKREFCTUhGaHllMS1PYk1kdFFXU3Y1ZWk5MWxWQlFjXzMzRlNqUVJOSzJLWGJvMTVpOWFEaTdtX0R6TE1RS3VHWDNqSGhqYi1COWZIWDRGZGN0ZUNJbXB4RHZib2VxSWFzR2ZlQ2dESjE5WG5YajROSDl4eEFfNlBCdHpNUWJJT3FfWHBrejcyYXpBQWtSSlQzMExOcGxLbno0QlhLSTZRUHZYcUVZdXdYNnRjdVNQWFVGMmFoQlg4Zm5RUmdRSFpwWnFyaGlqd3p5UjgzU3hCTENPMThVWk1Fcnc?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio stock price target reiterated at $20 by H.C. Wainwright", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQZkZ4X28wNThtMUR3VEZXTjlyYmpWd3BQWVJ3MUtYWXplcWVHeTNLRWNGbkItbmNUTDdFTVRpWGxfRWVSQWFCSVp5WjBuOUdIYXBGUTdkWl9NelZpMG9feVRpenFhM3FtTlFMd2JiazkwZ09SMWxfZExYd1otakFPWUFHSnMxX2luYjh6NkdSbTViNFZTYzhKVld3Vk1DM1hHTy1SeTh2V3U1VmUwNzdIT1Z2WldhLUpraHZLYVhKMA?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio Reports Encouraging Phase 1b Results for Budoprutug in ITP", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/climb-bio-reports-encouraging-phase-121117024.html", "source_name": "MT Newswires", "published_at": "2026-06-11T12:11:17+00:00", "published_display": "11 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/climb-bio-announces-initial-phase-110000292.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T11:00:00+00:00", "published_display": "11 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG raises Climb Bio stock price target to $20 on ITP trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQdnNjTEhvZlhDWG5pbll1a1o2Qm54dXd3LWV4dDZqQW5wT2JVTEpGNG9oa2hTQ3F1R3A4dGh3VGNDVEh3M1pkaWFJNlJ6TWhtbV9rNnJ2SXZMOTB4S2lSeHdqbjFpaS1VLXJJVGx5UWZfOHBLYVNPZDB4dVNaUHJWN2JteVZzRlotVHJmZ2VUM3JCN2ppeGY1UEhMQ1p3alNyTXZoVTg5OVgyQ3UtRnR3ZE53UHhqT2VHTHhIbVZuYkhmdw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim Initiates Climb Bio at Buy With $35 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/guggenheim-initiates-climb-bio-buy-101950133.html", "source_name": "MT Newswires", "published_at": "2026-06-08T10:19:50+00:00", "published_display": "08 Jun 2026 10:19", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Membranous Nephropathy Market Emerging as a High-Growth Healthcare Investment Space Through 2036 \u2013 DelveInsight | Roche, BeOne Medicines, Biogen, Vertex Pharma, AstraZeneca, Alexion Pharma, Climb Bio", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wJBVV95cUxQX3dDeVhiWlhuR3R0U2NITXRyYnB0UWR3RWZleVRpWGhqMTZHdm9XMTVGU3JRUldrSE9TRDJQRElMSFRvTjhlZ0c5eTRQbEw2WmwwNlpQbllMUXZhQkk1STNQbzRoQ3NRN05ZR2VjRFlFS0luajhCVklKbW5sRUJuQi10X19mcG9jai0ycTUzSk8zSHgybF8ya1c3VkszMGtsOTdQZkhBTjlzejd1UGJnR3ludHF5VUhJSmZfbU1SX2UzajE5VnVPNlg1TmdEdVdoTDctNUExTjQxakRjQmRtLXN6M2dNbkM5UEctQUFZSHk3VWdsa3AtWmJiaERCRjc0STVaUGNWa0hKUlQtNEJUNGxxcGMyTUZzNzZzdHkzRXdZLV9leEIyUGtuVWdJZC02aC1hLWVoSlpKVmhDeVJJU2ZhUEFSbVlWWUlFdlQwX1NOaXM?oc=5", "source_name": "Barchart.com", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/climb-bio-presents-clym116-initial-110000150.html", "source_name": "GlobeNewswire", "published_at": "2026-06-05T11:00:00+00:00", "published_display": "05 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/climb-bio-present-clym116-budoprutug-110000506.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T11:00:00+00:00", "published_display": "26 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect", "summary": "", "url": "https://finance.yahoo.com/m/42457d78-7d9a-3c8a-bc48-634a217dfc8d/climb-bio-teases-key.html", "source_name": "MarketBeat", "published_at": "2026-05-21T05:02:30+00:00", "published_display": "21 May 2026 05:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/climb-bio-present-budoprutug-clinical-110000536.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T11:00:00+00:00", "published_display": "14 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Climb Bio to Present at Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/climb-bio-present-upcoming-investor-110000395.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T11:00:00+00:00", "published_display": "12 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "$110M financing gives Climb Bio room for multiple 2026 drug data readouts", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQYW9tM2RHTGktbnZFUVpDMWJhaXF0UHd0ZWRleEpsTFNlNVZYZWhhN0ZqekFMb2xtbmJWTzJ0QTlfZmJXYlRRRGpQeWdiV1BqdnBNaklidnd2aEl5RXRqNTBjeWJYcGROTkJ3eER5d21WSFM0UDE3X1VvMG5hMFNWRHRIMWRSWm5OcjE2Z0JFU2RMXzZ1RnRfZGRwTERlWWFkWXlnTEduVDR2ZThucm5lQkxoS0IwaUFjR3dpTUNtQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQUFMwemtMdnRfR1pKWU9UXzk5LVNDVzd4dUNiaEQ4QmktUGk4S3pTU2RPUk1TcFBQWkFWN0h2am0xRHBVZktGRFBJYU5PRkJZRGIwVTFnVVBvSnZTVTdaUUpxQk1SV2IyYmFMeUJNVldKdG1UbTVQQ3dvYTNVUjJpT2JiTVdkd3NzSXFVQWZHUW1WVldweTJyUzN3aUY?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Climb Bio (CLYM) is One of the Best Performing Small Cap Stocks So Far in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQVmk0TV85VlVXOGgzeVpJYmZ5YlprVjQwQ05CazFIUHFRSnlWNk5EaTF6RlJHTWJyNnl1SjZzTFdVOXpNOTQ5YnItMXBEQ0dtQTZpcVpXbld1R253LWFmNElxZV9rdDE5bjhxZW56dUJxVDF0azhRWjY2dkx3UkxVOHNDaUx1d2dQMVdPNU9rY3A?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Institutional investors commit $110M in Climb Bio share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNYU90aW5BRVBNTVhvR1pBWEg5WnExNVJxU01WRHB4TTJvRzBXTG0tcWpXZzBiTjQ2cWtfc2xRdnVsdUZ3Q0doN01HZ1BXcnkwNWllZTdrRUIzc1VScWVueUZZbjZKNV9TNVdPOThnYU5pZnQ0cG92NHdSRlFVaktibjM5US1RT1JVX2pfbFRlXzdpbVMzbFBMdmRfQVBCblRFSFE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio, Inc. Announces $110.0 Million Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPSVJXby1KeldOeDNfN2ROQzVrXy1RN0RLYU9JeVNfTXp6V2dNSXk5YmNDRG04X2NLUmUyMVpJd1dBMVpKd1plVWJXVHAyOGZ5alVHRTR6cXVfVkJNYTBhY0d0bVktbzEtYUxyeTI2aTE3RGpxdzJ3N25zV2FvcERiUGpwVTBXNVNyVmRFUDh2S0NBdXE0YzNJdk8wbXJWejZadDdtMmlmWlZNQ0pMdFc3SDVrVWwzWlQwclhLRjRvUnNtcERIZmc?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "FDA Fast Track and a BTIG Buy; Is Climb Bio (CLYM) a Must-Buy Small Cap Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNRjM2Q0dRX0twRHF4d2dtVXVac3dTOFRzQ0ZSWjVRaEQ0SGM1SmxfZmZ0U3hyMjkzcmhsc3ZZbkpzc2tYbTBLNEI3MGVnZmlMc1doV1hLOWhFS1R5ZWV6Sm9hWktramtfZndBOV9ObWdzWDdSSFhVM012Rko1SWtzS1FGQzdDdkNQaElvVVNCWHk5MnNHRzdB?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions Underway (CLYM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPcmdDZVhJc3lxS1FqZmZFZnM2WW5mWDJTQl9zSzY2WDdKWTZ0X0NKY3JUNW5LODdPelViZlFFM0JFUUVUWEw3al91czN2SlQ0el9UZ2hvdmpMS2hOOUIyRXJENVVmLXVaWVF2emhMSlVMY3NDYmtWa0JuTG9RRDd2TDVMa002TzJJcEZQVG9GUFZkR0RoaGZvZlFHNDhLdlExb3dEXzkxaUlSejg5SGtkUG9DcktidTA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio, Inc. (CLYM) Leadership & Management Team Analysis", "summary": "This article provides an analysis of Climb Bio, Inc.'s (CLYM) leadership and management team. It details compensation for CEO Aoife Brennan, management and board tenure, and lists recent company updates including executive changes, regulatory designations, and financial activitie", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-clym/climb-bio/management", "source_name": "Simply Wall Street", "published_at": "2026-04-13T12:40:21", "published_display": "13 Apr 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Climb Bio Stock Pre-Market (+6.4%): Wedbush Initiates at Outperform, $12 Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNTkwxSEpKT0JlM29uU2J1clRCOWVKM1E4cnJfNVhMNHdQVjBWQ0YwSm01SDhqSXBlakQ3REJRV1RHRklrTWc3cmdVVndLRUJsVTMzMTF5Y3lDSTdKdzhxSmN4SE5mX3FIWksyeE1uNjRQdGNyeHpPT1ZJNU4zM0tRLWM5dGNyVXRSOEdkRzZETFBkWERzZnhQWmFGUUhlZDRVbDFoVzVnaHMzREx6WFBrRzFpVWxWbE5kTThZUE13RUhjVDlHb2FpVjhLLXF2dw?oc=5", "source_name": "Trefis", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ELYM Stock: Transition from Eliem Therapeutics to Climb Bio", "summary": "Eliem Therapeutics, formerly known as ELYM, has rebranded to Climb Bio (CLYM) and shifted its strategic focus from neurology to autoimmune disease treatments. This transformation followed the acquisition of Tenet Medicines in mid-2024, which brought budoprutug, a promising therap", "url": "https://www.bitget.com/wiki/elym-stock", "source_name": "Bitget", "published_at": "2026-02-12T12:10:27", "published_display": "12 Feb 2026 12:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Climb Bio's (NASDAQ:CLYM) Cash Burn Situation", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNN0hnLVhSTWtJNF96X2EwbzJ3MV82dFF2T2NhNEpQenhvTW1NUTktMS1BN0VyeDdweUY2b0dGVkdod3dHNVlZSi04VTdSSWM4YnJrWXQ4LURQNmM5bk54ZXFlYWFoUTBtSEdLZGNvR0NuM0ZMdE95S19RLTlpVGFxNE9zTm9VZzJ2cjZZS0xTakdOeW53S2FTQTU1OE10LWN4bkQxWUlSb0dVNHBBQ0JVbDNWQmE4UzdwbHFaSG5vcXlveG5oVzBOcDNHa3BzQW5WaXZoSU9xbDF1S1nSAeABQVVfeXFMUFg4cmFPX2ZYcFczOWJWZER3Z3IwOWJhcklYaEZLQTBoeC1XemlJbFlPUW5LTVl4dUtRSEtIX3pOY3lnQnJCNXI1cS1oR2psYjdjbjNHNklMVlY3b0RNTkxGUkRELTNjYzFVRkk0MjBtSUo5RGs5R2hGRFFHdjJJVTZ3cU9aMF9iV2JIaklJVS1VUEVWLVRkeC1FRHdpeHJqOE5yM3JCXzNwRnpZRlVzenVSVFp4eXRhQkZQcW9rR1ZvR1QwUHBNUVVoMWtEQ1BubnZXZVJ0dW01UzROZ2gwOW4?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-07T08:00:00+00:00", "published_display": "07 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio, Inc. (NASDAQ:CLYM) Shares Could Be 45% Below Their Intrinsic Value Estimate", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTFA4NTc1elJwVGkwNnhTRmYySDEtNHUyYVQ0YmM5VEhDZzdiaEpKSkZqSFNsYUZmS082OTdTRmZjbXIzejlOcUdKNHlXLVFhM3AwRUNUQVljbG5wcHE0T3NZYXJpZ3R3RFlmYndHSEdSYy1nVEdZeVRRSy1Pdw?oc=5", "source_name": "Market source", "published_at": "2026-01-24T08:00:00+00:00", "published_display": "24 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio\u2019s (CLYM) Budoprutug Across Clinical Tracks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOZkpmWlphZDNfN1R2aTlZYzl5b0xPc1VrYjJUVkcwV1hNNnVsbllmUWEzcnFwREtwbkRGRms3b1dKUUdNWmxnNDljUnhBQWk3cW1zSGlUbHZyZEtiTnJUVkhWMno4ZlE2MmtMcFRhSFpTakkzMlMtdTZxaE42WWFEdg?oc=5", "source_name": "Market source", "published_at": "2025-12-31T08:00:00+00:00", "published_display": "31 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Retail investors in Climb Bio, Inc. (NASDAQ:CLYM) are its biggest bettors, and their bets paid off as stock gained 15% last week", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-28T08:00:00+00:00", "published_display": "28 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eliem Therapeutics Changes Name to Climb Bio", "summary": "Eliem Therapeutics, Inc. has officially changed its corporate name to Climb Bio, Inc. and will trade under the new Nasdaq ticker symbol \"CLYM\" starting October 3rd. This rebranding signifies the company's refocused mission on developing treatments for immune-mediated diseases, wi", "url": "https://finance.yahoo.com/news/eliem-therapeutics-changes-name-climb-230452558.html", "source_name": "Market source", "published_at": "2024-10-02T23:04:52", "published_display": "02 Oct 2024 23:04", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.", "summary": "Eliem Therapeutics, Inc. has announced its rebranding to Climb Bio, Inc., effective October 3, 2024, trading under the new Nasdaq symbol \"CLYM.\" This change reflects the company's refocused mission to develop treatments for immune-mediated diseases, following its acquisition of T", "url": "https://www.globenewswire.com/news-release/2024/10/02/2957013/0/en/eliem-therapeutics-announces-rebranding-and-corporate-name-change-to-climb-bio-inc.html", "source_name": "GlobeNewswire", "published_at": "2024-10-02T09:00:00", "published_display": "02 Oct 2024 09:00", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "FMR LLC's Strategic Acquisition of Climb Bio Inc Shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPYU9PTHk0aUxpWUJKR1NrTGdwd255WTNXME5oa0xISTdfSVphTnB6bTZCSktPUmhLUXFIQWoySUMyUWlnLUZEa1FDS1MwaTN0bDY1eGZEWElXX1EtVHNBbklPbzdkVlQ5ZnhPVk0zMElQTVNmYnBKckV2V3dGdWVTN0xUV3pFYmVidi1Fc3JmR2FFX0h1cjF0SQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T00:59:19+00:00", "published_display": "15 Jul 2026 00:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Climb Bio Inc For: 1 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxOQ3J3bUZGT0dsZDhhQ2ZfTmw5WXFZbVBCOUgxZHVTVk8zTjhwZnpoZTBnSGlSc3dyNExSRkRMaGp6QTgzTHpMMmx1MWdPcDZ5U3dOVWVtd0FVMFgwcVpHTUdmbnhfcjRSN1NGT2ozY3dYR1JxbmE2T2ZkdW04QlBycVVyZ3NjMlVzS2VnNnd1aXc5ZEp3VmZv?oc=5", "source_name": "Investing.com UK", "published_at": "2026-07-01T21:57:23+00:00", "published_display": "01 Jul 2026 21:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio Insider Sold Shares Worth $406,979, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/climb-bio-insider-sold-shares-081533939.html", "source_name": "MT Newswires", "published_at": "2026-07-01T08:15:33+00:00", "published_display": "01 Jul 2026 08:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "70,284 Climb Bio (CLYM) share options granted for RA Capital-related funds", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQMVpMb2dHblV1OHNZR1VoU19BTjRKaXlMYm0teDhva3pmN1NqMmRIQ3RTVDhBcjFPdjd5M3JQVVBIZlVDRE5yajU3Skp3R1B4c09LaTA3TlVlOS1LZU82emc5RDVyYTFSRUltZTM5TUpwNm85YTRlX0VFdEkweFBHN1Q1b3I2LXRsWThaVmlOOS13Y0hUQWxHcW11VzVKRHVxcS1mM1RJdWRhUjg?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Climb Bio Inc For: 30 June By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPMk5YUUI4SkxIVjlENjdmUHY2TDF4TWtUWnlpeVdfRVk5ZzZudHBNb05QQjllLUxYQlZiT3hyQkpMd25wVVhMZl90VWNZS3ZRN0RqWXZqd2w5aWc4MVI2ZnNvWVN1MXBZMDE2dzhpSGtzNlozVGV6clVJTjJWQ3o4dWIyLVRJNG9IcUtNNW54T0ZXU2JYZ2x5RA?oc=5", "source_name": "Investing.com UK", "published_at": "2026-07-01T00:02:13+00:00", "published_display": "01 Jul 2026 00:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 2000 Index", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNX25QdlB1MG12TzVmNDRLWVZqdzRVZTRPNFltdEFYem5LUmRiODZ4aHlHLWZ4QnF1S0tkajg2X3E5dHUtU0MyYzNVUW1ITm40cUxvRTZIQ3lFWTRaTVNqSTlIRGFkRzZDdnJiSno4QnpuQWl2UlU3dFJ3NnlwX21kM3hDbzVWdHhVUmp6N0dHV0NzM2tBYWJRdy1rLWtFZHZ4bDQtQ0k2R292Mlg3?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-29T21:45:55+00:00", "published_display": "29 Jun 2026 21:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 3000E Growth Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQTmVxblFQUGJpQjBpZkRFMXVscWVVRzJKNjNIcTZlWEpNcy10d0xkZ2lFWkRReG9lLXpNYlRHMWx2em9Ya0pMYWMxd19Nc0lEaGVPOWtyQXlxOWtDM250ZldUeEYzcmtnWFl6SU5oNmQycHVGWmVsd3Z2MUVmNWxYNWFUOW0wM0c5blJrU2dvaWxqT3B0NFVnSGtMbVNtem9DaWt0bmhyTHVtN0FfMlhKUm1CVHNudVZDU09PWQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-29T08:46:02+00:00", "published_display": "29 Jun 2026 08:46", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio, Inc.(NasdaqGM: CLYM) added to Russell 3000 Growth Benchmark", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggJBVV95cUxNME1DMzBaZ0EzZ1N1enpxZGhpeG1PUW5FV3hOQktweEpKREFCTUhGaHllMS1PYk1kdFFXU3Y1ZWk5MWxWQlFjXzMzRlNqUVJOSzJLWGJvMTVpOWFEaTdtX0R6TE1RS3VHWDNqSGhqYi1COWZIWDRGZGN0ZUNJbXB4RHZib2VxSWFzR2ZlQ2dESjE5WG5YajROSDl4eEFfNlBCdHpNUWJJT3FfWHBrejcyYXpBQWtSSlQzMExOcGxLbno0QlhLSTZRUHZYcUVZdXdYNnRjdVNQWFVGMmFoQlg4Zm5RUmdRSFpwWnFyaGlqd3p5UjgzU3hCTENPMThVWk1Fcnc?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-28T07:00:00+00:00", "published_display": "28 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio stock price target reiterated at $20 by H.C. Wainwright", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQZkZ4X28wNThtMUR3VEZXTjlyYmpWd3BQWVJ3MUtYWXplcWVHeTNLRWNGbkItbmNUTDdFTVRpWGxfRWVSQWFCSVp5WjBuOUdIYXBGUTdkWl9NelZpMG9feVRpenFhM3FtTlFMd2JiazkwZ09SMWxfZExYd1otakFPWUFHSnMxX2luYjh6NkdSbTViNFZTYzhKVld3Vk1DM1hHTy1SeTh2V3U1VmUwNzdIT1Z2WldhLUpraHZLYVhKMA?oc=5", "source_name": "Investing.com", "published_at": "2026-06-24T07:00:00+00:00", "published_display": "24 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio Reports Encouraging Phase 1b Results for Budoprutug in ITP", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/climb-bio-reports-encouraging-phase-121117024.html", "source_name": "MT Newswires", "published_at": "2026-06-11T12:11:17+00:00", "published_display": "11 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/climb-bio-announces-initial-phase-110000292.html", "source_name": "GlobeNewswire", "published_at": "2026-06-11T11:00:00+00:00", "published_display": "11 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BTIG raises Climb Bio stock price target to $20 on ITP trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQdnNjTEhvZlhDWG5pbll1a1o2Qm54dXd3LWV4dDZqQW5wT2JVTEpGNG9oa2hTQ3F1R3A4dGh3VGNDVEh3M1pkaWFJNlJ6TWhtbV9rNnJ2SXZMOTB4S2lSeHdqbjFpaS1VLXJJVGx5UWZfOHBLYVNPZDB4dVNaUHJWN2JteVZzRlotVHJmZ2VUM3JCN2ppeGY1UEhMQ1p3alNyTXZoVTg5OVgyQ3UtRnR3ZE53UHhqT2VHTHhIbVZuYkhmdw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim Initiates Climb Bio at Buy With $35 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/guggenheim-initiates-climb-bio-buy-101950133.html", "source_name": "MT Newswires", "published_at": "2026-06-08T10:19:50+00:00", "published_display": "08 Jun 2026 10:19", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Membranous Nephropathy Market Emerging as a High-Growth Healthcare Investment Space Through 2036 \u2013 DelveInsight | Roche, BeOne Medicines, Biogen, Vertex Pharma, AstraZeneca, Alexion Pharma, Climb Bio", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wJBVV95cUxQX3dDeVhiWlhuR3R0U2NITXRyYnB0UWR3RWZleVRpWGhqMTZHdm9XMTVGU3JRUldrSE9TRDJQRElMSFRvTjhlZ0c5eTRQbEw2WmwwNlpQbllMUXZhQkk1STNQbzRoQ3NRN05ZR2VjRFlFS0luajhCVklKbW5sRUJuQi10X19mcG9jai0ycTUzSk8zSHgybF8ya1c3VkszMGtsOTdQZkhBTjlzejd1UGJnR3ludHF5VUhJSmZfbU1SX2UzajE5VnVPNlg1TmdEdVdoTDctNUExTjQxakRjQmRtLXN6M2dNbkM5UEctQUFZSHk3VWdsa3AtWmJiaERCRjc0STVaUGNWa0hKUlQtNEJUNGxxcGMyTUZzNzZzdHkzRXdZLV9leEIyUGtuVWdJZC02aC1hLWVoSlpKVmhDeVJJU2ZhUEFSbVlWWUlFdlQwX1NOaXM?oc=5", "source_name": "Barchart.com", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/climb-bio-presents-clym116-initial-110000150.html", "source_name": "GlobeNewswire", "published_at": "2026-06-05T11:00:00+00:00", "published_display": "05 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/climb-bio-present-clym116-budoprutug-110000506.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T11:00:00+00:00", "published_display": "26 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect", "summary": "", "url": "https://finance.yahoo.com/m/42457d78-7d9a-3c8a-bc48-634a217dfc8d/climb-bio-teases-key.html", "source_name": "MarketBeat", "published_at": "2026-05-21T05:02:30+00:00", "published_display": "21 May 2026 05:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/climb-bio-present-budoprutug-clinical-110000536.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T11:00:00+00:00", "published_display": "14 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio to Present at Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/climb-bio-present-upcoming-investor-110000395.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T11:00:00+00:00", "published_display": "12 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$110M financing gives Climb Bio room for multiple 2026 drug data readouts", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQYW9tM2RHTGktbnZFUVpDMWJhaXF0UHd0ZWRleEpsTFNlNVZYZWhhN0ZqekFMb2xtbmJWTzJ0QTlfZmJXYlRRRGpQeWdiV1BqdnBNaklidnd2aEl5RXRqNTBjeWJYcGROTkJ3eER5d21WSFM0UDE3X1VvMG5hMFNWRHRIMWRSWm5OcjE2Z0JFU2RMXzZ1RnRfZGRwTERlWWFkWXlnTEduVDR2ZThucm5lQkxoS0IwaUFjR3dpTUNtQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQUFMwemtMdnRfR1pKWU9UXzk5LVNDVzd4dUNiaEQ4QmktUGk4S3pTU2RPUk1TcFBQWkFWN0h2am0xRHBVZktGRFBJYU5PRkJZRGIwVTFnVVBvSnZTVTdaUUpxQk1SV2IyYmFMeUJNVldKdG1UbTVQQ3dvYTNVUjJpT2JiTVdkd3NzSXFVQWZHUW1WVldweTJyUzN3aUY?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Climb Bio (CLYM) is One of the Best Performing Small Cap Stocks So Far in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQVmk0TV85VlVXOGgzeVpJYmZ5YlprVjQwQ05CazFIUHFRSnlWNk5EaTF6RlJHTWJyNnl1SjZzTFdVOXpNOTQ5YnItMXBEQ0dtQTZpcVpXbld1R253LWFmNElxZV9rdDE5bjhxZW56dUJxVDF0azhRWjY2dkx3UkxVOHNDaUx1d2dQMVdPNU9rY3A?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Institutional investors commit $110M in Climb Bio share sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxNYU90aW5BRVBNTVhvR1pBWEg5WnExNVJxU01WRHB4TTJvRzBXTG0tcWpXZzBiTjQ2cWtfc2xRdnVsdUZ3Q0doN01HZ1BXcnkwNWllZTdrRUIzc1VScWVueUZZbjZKNV9TNVdPOThnYU5pZnQ0cG92NHdSRlFVaktibjM5US1RT1JVX2pfbFRlXzdpbVMzbFBMdmRfQVBCblRFSFE?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio, Inc. Announces $110.0 Million Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxPSVJXby1KeldOeDNfN2ROQzVrXy1RN0RLYU9JeVNfTXp6V2dNSXk5YmNDRG04X2NLUmUyMVpJd1dBMVpKd1plVWJXVHAyOGZ5alVHRTR6cXVfVkJNYTBhY0d0bVktbzEtYUxyeTI2aTE3RGpxdzJ3N25zV2FvcERiUGpwVTBXNVNyVmRFUDh2S0NBdXE0YzNJdk8wbXJWejZadDdtMmlmWlZNQ0pMdFc3SDVrVWwzWlQwclhLRjRvUnNtcERIZmc?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA Fast Track and a BTIG Buy; Is Climb Bio (CLYM) a Must-Buy Small Cap Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNRjM2Q0dRX0twRHF4d2dtVXVac3dTOFRzQ0ZSWjVRaEQ0SGM1SmxfZmZ0U3hyMjkzcmhsc3ZZbkpzc2tYbTBLNEI3MGVnZmlMc1doV1hLOWhFS1R5ZWV6Sm9hWktramtfZndBOV9ObWdzWDdSSFhVM012Rko1SWtzS1FGQzdDdkNQaElvVVNCWHk5MnNHRzdB?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions Underway (CLYM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPcmdDZVhJc3lxS1FqZmZFZnM2WW5mWDJTQl9zSzY2WDdKWTZ0X0NKY3JUNW5LODdPelViZlFFM0JFUUVUWEw3al91czN2SlQ0el9UZ2hvdmpMS2hOOUIyRXJENVVmLXVaWVF2emhMSlVMY3NDYmtWa0JuTG9RRDd2TDVMa002TzJJcEZQVG9GUFZkR0RoaGZvZlFHNDhLdlExb3dEXzkxaUlSejg5SGtkUG9DcktidTA?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio, Inc. (CLYM) Leadership & Management Team Analysis", "summary": "This article provides an analysis of Climb Bio, Inc.'s (CLYM) leadership and management team. It details compensation for CEO Aoife Brennan, management and board tenure, and lists recent company updates including executive changes, regulatory designations, and financial activitie", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-clym/climb-bio/management", "source_name": "Simply Wall Street", "published_at": "2026-04-13T12:40:21", "published_display": "13 Apr 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio Stock Pre-Market (+6.4%): Wedbush Initiates at Outperform, $12 Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNTkwxSEpKT0JlM29uU2J1clRCOWVKM1E4cnJfNVhMNHdQVjBWQ0YwSm01SDhqSXBlakQ3REJRV1RHRklrTWc3cmdVVndLRUJsVTMzMTF5Y3lDSTdKdzhxSmN4SE5mX3FIWksyeE1uNjRQdGNyeHpPT1ZJNU4zM0tRLWM5dGNyVXRSOEdkRzZETFBkWERzZnhQWmFGUUhlZDRVbDFoVzVnaHMzREx6WFBrRzFpVWxWbE5kTThZUE13RUhjVDlHb2FpVjhLLXF2dw?oc=5", "source_name": "Trefis", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ELYM Stock: Transition from Eliem Therapeutics to Climb Bio", "summary": "Eliem Therapeutics, formerly known as ELYM, has rebranded to Climb Bio (CLYM) and shifted its strategic focus from neurology to autoimmune disease treatments. This transformation followed the acquisition of Tenet Medicines in mid-2024, which brought budoprutug, a promising therap", "url": "https://www.bitget.com/wiki/elym-stock", "source_name": "Bitget", "published_at": "2026-02-12T12:10:27", "published_display": "12 Feb 2026 12:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Watching Climb Bio's (NASDAQ:CLYM) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-07T08:00:00+00:00", "published_display": "07 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Climb Bio, Inc. (NASDAQ:CLYM) Shares Could Be 45% Below Their Intrinsic Value Estimate", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTFA4NTc1elJwVGkwNnhTRmYySDEtNHUyYVQ0YmM5VEhDZzdiaEpKSkZqSFNsYUZmS082OTdTRmZjbXIzejlOcUdKNHlXLVFhM3AwRUNUQVljbG5wcHE0T3NZYXJpZ3R3RFlmYndHSEdSYy1nVEdZeVRRSy1Pdw?oc=5", "source_name": "Market source", "published_at": "2026-01-24T08:00:00+00:00", "published_display": "24 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio\u2019s (CLYM) Budoprutug Across Clinical Tracks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAFBVV95cUxOZkpmWlphZDNfN1R2aTlZYzl5b0xPc1VrYjJUVkcwV1hNNnVsbllmUWEzcnFwREtwbkRGRms3b1dKUUdNWmxnNDljUnhBQWk3cW1zSGlUbHZyZEtiTnJUVkhWMno4ZlE2MmtMcFRhSFpTakkzMlMtdTZxaE42WWFEdg?oc=5", "source_name": "Market source", "published_at": "2025-12-31T08:00:00+00:00", "published_display": "31 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Retail investors in Climb Bio, Inc. (NASDAQ:CLYM) are its biggest bettors, and their bets paid off as stock gained 15% last week", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-28T08:00:00+00:00", "published_display": "28 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eliem Therapeutics Changes Name to Climb Bio", "summary": "Eliem Therapeutics, Inc. has officially changed its corporate name to Climb Bio, Inc. and will trade under the new Nasdaq ticker symbol \"CLYM\" starting October 3rd. This rebranding signifies the company's refocused mission on developing treatments for immune-mediated diseases, wi", "url": "https://finance.yahoo.com/news/eliem-therapeutics-changes-name-climb-230452558.html", "source_name": "Market source", "published_at": "2024-10-02T23:04:52", "published_display": "02 Oct 2024 23:04", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.", "summary": "Eliem Therapeutics, Inc. has announced its rebranding to Climb Bio, Inc., effective October 3, 2024, trading under the new Nasdaq symbol \"CLYM.\" This change reflects the company's refocused mission to develop treatments for immune-mediated diseases, following its acquisition of T", "url": "https://www.globenewswire.com/news-release/2024/10/02/2957013/0/en/eliem-therapeutics-announces-rebranding-and-corporate-name-change-to-climb-bio-inc.html", "source_name": "GlobeNewswire", "published_at": "2024-10-02T09:00:00", "published_display": "02 Oct 2024 09:00", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 102, "total_relevant": 43, "sentiment_summary": {"positive": 11, "negative": 1, "neutral": 31, "score": 55, "total": 43, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 13.55, "count": 24}, {"event": "earnings", "label": "Earnings", "weight": 4.4, "count": 10}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 11, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 14.0, "latest_week": "2026-07-10", "one_week_move": 8.5, "four_week_move": 22.4, "twelve_week_move": 52.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 2.100642, "market_dynamics_buy_signal": false, "relative_strength": 127.694476, "fair_value_gap": 234.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 47.1253, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+8.5% over one week, +22.4% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "GlobeNewswire", "count": 7}, {"label": "simplywall.st", "count": 4}, {"label": "MT Newswires", "count": 3}, {"label": "Stock Titan", "count": 3}, {"label": "marketscreener.com", "count": 3}, {"label": "Investing.com UK", "count": 2}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 35}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 24}, {"label": "Earnings", "count": 10}, {"label": "Analyst action", "count": 4}, {"label": "Deals and strategy", "count": 3}, {"label": "Regulatory and legal", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "35", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+8.5% over one week, +22.4% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "FMR LLC's Strategic Acquisition of Climb Bio Inc Shares"}], "updated_at": "2026-07-16T03:02:58.906807+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}